Cargando…

Approach to systemic therapy in advanced hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Sankar, Kamya, Gong, Jun, Kosari, Kambiz, Nissen, Nicholas N., Yang, Ju Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745627/ https://www.ncbi.nlm.nih.gov/pubmed/36523939 http://dx.doi.org/10.21037/hbsn-22-530

Ejemplares similares

Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact
por: Govalan, Rajalakshmi, et al.
Publicado: (2021)

Systemic therapy in advanced hepatocellular carcinoma
por: Ahn, Joseph C., et al.
Publicado: (2023)

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure
por: Farsad, Khashayar, et al.
Publicado: (2020)

New developments in ablation therapy for hepatocellular carcinoma: combination with systemic therapy and radiotherapy
por: Numata, Kauzshi, et al.
Publicado: (2022)

Combination therapies for advanced hepatocellular carcinoma: a beacon of light or a castle in the air
por: Rai, Vikrant, et al.
Publicado: (2022)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
por: Ji, Jun Ho, et al.
Publicado: (2023)

Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
por: Nipp, Ryan, et al.
Publicado: (2016)

Hepatocellular carcinoma therapy finds a channel on the radio
por: Camacho, Javier
Publicado: (2019)

The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma
por: Parent, Romain, et al.
Publicado: (2019)

Evolution of systemic therapy for advanced-stage hepatocellular carcinoma
por: Hur, Moon Haeng, et al.
Publicado: (2022)

Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
por: Ozer, Muhammet, et al.
Publicado: (2023)

Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma
por: Aitcheson, Gabriella, et al.
Publicado: (2021)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future
por: Sarkar, Devanand
Publicado: (2022)

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
por: Kudo, Masatoshi
Publicado: (2018)

Recent advances in systemic therapy for hepatocellular carcinoma
por: Zhang, Huajun, et al.
Publicado: (2022)

Making cancer fat: reprogramming of lipid metabolism by CD147 in hepatocellular carcinoma
por: Ju, Hye-Lim, et al.
Publicado: (2016)

Revisit the signatures of γδ T cells in hepatocellular carcinoma
por: Gao, Yanan, et al.
Publicado: (2022)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Cancer stem cells in hepatocellular carcinomas
por: Das, Prasenjit, et al.
Publicado: (2015)

Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
por: Girardi, Daniel M., et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

New Biomarkers for Early Detection of Hepatocellular Carcinoma
por: Yoshida, Katsunori
Publicado: (2015)

Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
por: Petrizzo, Annacarmen, et al.
Publicado: (2016)

Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure
por: Kim, Nalee, et al.
Publicado: (2022)

Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials
por: Lv, Jia-Wei, et al.
Publicado: (2019)

Racial Disparities and Molecular Insights in Translocation Renal Cell Carcinoma: Advancing Understanding and Treatment Approaches
por: Campbell, Patrick, et al.
Publicado: (2023)

Neoadjuvant targeted therapy for advanced renal cell carcinoma: Where do we stand?
por: Grivas, Nikolaos K.
Publicado: (2019)

Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies
por: Makary, Mina S., et al.
Publicado: (2020)

Hepatocellular carcinoma: H-Prune gene regulatory networks
por: de Antonellis, Pasqualino
Publicado: (2019)

IL-11 drives postsurgical hepatocellular carcinoma recurrence
por: Lauko, Adam, et al.
Publicado: (2019)

Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia
por: Mancuso, Andrea
Publicado: (2020)

Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2efndbsac5fqdnlca7c02cahve